OR WAIT null SECS
A report from Business Standard highlighted India’s recent growth in the pharma sector.
A recent report from Sohini Das of Business Standard found that revenue and earnings before interest, tax, depreciation, and amortization (EBITDA) projects that the Indian pharmaceutical industry grew between 14%–21% in the fourth quarter of the 2022–2023 fiscal year (see Table I).
Citing data from Bloomberg, the report found that the Indian market as a whole posted 11% growth. However, Das noted that because of price control and field force addition, upcoming EBITDA statistics might dip slightly in upcoming quarters.